Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Embibatinib in Healthy Participants
NCT07838987Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TERN-701 in chronic myeloid leukemia (CML) (19 cohorts), sponsored by Merck & Co. Primary endpoints: Treatment Emergent Adverse Events at 102 days, Discontinuations due to Adverse Events at 102 days and 12 more. Started Dec 2023; status: completed.
02
Drugs
TERN-701
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07838987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838987.